News

Chandra Briggman among the Virginia Best Black Business Leaders

Richmond, VA /Virginia Business/ – Black History Month traces its origins to an annual weeklong observance started in 1926 by historian and scholar Carter G. Woodson, a Virginia native. And since then, the February celebration of Black history makers and events has been intertwined with commemorating successful business icons like fellow Virginia-born greats Maggie Walker and Booker T. Washington.

With this in mind, Virginia Business presents our 2023 Virginia Black Business Leaders Awards, recognizing a reader-nominated group of some of the state’s most accomplished Black executives. On this inaugural list are 17 leaders, chosen from 108 nominated executives in finance, federal contracting, higher education, law, technology and other sectors. Our editorial team selected the 17 winners, scoring nominations based on factors including overall professional achievement, community impact and mentoring.

Chandra Briggman, President and CEO, Activation Capital, RichmondThe leader since 2020 of a Richmond-based innovation incubator that includes a biotech park, startup development and a newly invigorate

d cluster accelerator for pharmaceutical research and manufacturing, Briggman is off to a fast start. Growing up in a town of 2,000 in rural South Carolina, she was inspired by her parents to pursue innovation.

“Neither one of my parents had the opportunity to go to college,” Briggman says. “I consider them two of the smartest people I know. They were doers and experimenters, and that foundation was important.”

After college, Briggman worked for the U.S. Postal Service, where she learned about the intersection of service and technology, then for a Boston nonprofit promoting entrepreneurship. At Activation Capital, her role is “to manufacture entrepreneurs at scale,” she says — including recently landing a $53 million federal grant to expand manufacturing and development of pharmaceuticals in the Richmond region.

Read more here.

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these